Review of: "Targeting Alzheimer's disease hallmarks with the Nrf2 activator Isoeugenol"

Amelia Cataldi[1]

1 University of Chieti-Pescara

Potential competing interests: No potential competing interests to declare.

The manuscript :"Targeting Alzheimer's disease hallmarks with the Nrf2 activator Isoeugenol" include a lot of data and is well written. I have only few issues.

- Point 3.3 and Fig.3.Why authors state that fig.3C shows a GSK3beta overactivation since its phosphorylated levels are significantly reduced in N2 a-APPwe cell model? At the same time they state Akt activation anfd GSK3 beta inactivation upon ISO treatment for 30 min, since after 30 min both pAKT/AKT e pGSKbeta/GSK3beta levels are increased by ISO treatment?
- Why in new Fig. 13 is shown that intranasally administration of Isoeugenol seems modifies Abeta40 peptide in APP/PS1 transgenic animals and in the discussion section is reported that both Abeta 40 and Abeta 42 are reduced by the treatment?

Minor concerns.

Authors should correct legend to fig 12 by adding :"…on body and brain tissue weight…"

Authors should correct the numbering of the figures:12>13 and so on and at Point 3.9 linee 3,6 and 7 10>13.

Once these issues are clarified,I suggest this paper for publication

Best regards,s

Amelia Cataldi PhDincerely